For research use only. Not for therapeutic Use.
ARCC-4(CAT: I016359) is a potent and selective inhibitor of the E3 ubiquitin ligase RNF146, widely utilized in cancer and neurodegenerative disease research. By targeting RNF146, ARCC-4 disrupts PARylation-mediated ubiquitination processes, providing insights into cellular signaling, protein degradation, and DNA repair pathways. Researchers leverage this compound to study RNF146’s role in tumor progression, Wnt/β-catenin signaling, and neuronal survival. Its high specificity and effectiveness make ARCC-4 a valuable tool for preclinical studies focused on understanding the biological functions of RNF146 and exploring therapeutic interventions for diseases involving dysregulated ubiquitin-proteasome systems.
Catalog Number | I016359 |
CAS Number | 1973403-00-7 |
Molecular Formula | C₅₃H₅₆F₃N₇O₇S₂ |
Purity | ≥95% |
Target | Vitamin D Related/Nuclear Receptor |
IUPAC Name | (2S,4R)-1-[(2S)-2-[[2-[4-[4-[4-[3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl]phenyl]phenoxy]butoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide |
InChI | InChI=1S/C53H56F3N7O7S2/c1-32-45(72-31-59-32)36-11-9-33(10-12-36)28-58-47(66)43-26-40(64)29-61(43)48(67)46(51(2,3)4)60-44(65)30-69-23-7-8-24-70-41-21-16-35(17-22-41)34-13-18-38(19-14-34)63-50(71)62(49(68)52(63,5)6)39-20-15-37(27-57)42(25-39)53(54,55)56/h9-22,25,31,40,43,46,64H,7-8,23-24,26,28-30H2,1-6H3,(H,58,66)(H,60,65)/t40-,43+,46-/m1/s1 |
InChIKey | DUPAJELXESPTNF-PPZGWQTASA-N |
SMILES | CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)COCCCCOC4=CC=C(C=C4)C5=CC=C(C=C5)N6C(=S)N(C(=O)C6(C)C)C7=CC(=C(C=C7)C#N)C(F)(F)F)O |